

Once-per-week selinexor, bortezomib, and dexamethasone  
bortezomib and dexamethasone in patients with multiple myeloma: an  
open-label, phase 3 trial

Lancet, The

396, 1563-1573

DOI: [10.1016/s0140-6736\(20\)32292-3](https://doi.org/10.1016/s0140-6736(20)32292-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	MYC inhibitors in multiple myeloma. , 2021, 4, 842-865.		5
2	Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. Annals of Hematology, 2021, 100, 725-734.	1.8	12
3	Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. Clinical Cancer Research, 2021, 27, 3307-3316.	7.0	17
4	How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 291-309.	3.8	27
5	When and How to Treat Relapsed Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 358-375.	3.8	9
6	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
7	Novel Experimental Drugs for Treatment of Multiple Myeloma. Journal of Experimental Pharmacology, 2021, Volume 13, 245-264.	3.2	16
8	Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export. Clinical Pharmacokinetics, 2021, 60, 957-969.	3.5	11
9	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematology,the, 2021, 8, e299-e304.	4.6	10
10	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. American Journal of Hematology, 2021, 96, 690-697.	4.1	13
11	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	17.0	11
12	Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers, 2021, 13, 1686.	3.7	25
13	Multiple myeloma triplet therapies: baseline characteristics and control groups " Authors' reply. Lancet, The, 2021, 397, 1621-1623.	13.7	1
14	Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet, The, 2021, 397, 1621.	13.7	0
15	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	4.1	16
16	Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet, The, 2021, 397, 1620-1621.	13.7	1
17	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
18	Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e460-e463.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Strategies to Overcome High-Risk Multiple Myeloma. Cancer Journal (Sudbury, Mass ), 2021, 27, 201-204.	2.0	0
20	US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 493-502.	1.9	1
21	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	2.4	1
22	Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2021, 62, 2777-2784.	1.3	2
23	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1176, 122781.	2.3	2
24	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Design, Development and Therapy, 2021, Volume 15, 2401-2415.	4.3	26
25	Updates in the management of relapsed/refractory multiple myeloma. Journal of Oncology Pharmacy Practice, 2021, 27, 1477-1490.	0.9	2
26	Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment of Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents and Monoclonal Antibodies. , 0, , .		0
27	Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma. Journal of Blood Medicine, 2021, Volume 12, 529-550.	1.7	5
28	Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. JCO Oncology Practice, 2021, 17, 415-418.	2.9	2
29	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM2 study. Cancer, 2021, 127, 4198-4212.	4.1	89
30	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	4.1	7
31	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	4.1	15
32	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	5
33	The "comeback"™ of Selinexor: From toxic to tolerable. Current Problems in Cancer, 2021, 46, 100789.	2.0	2
34	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. International Journal of Cancer, 2021, 149, 1980-1996.	5.1	25
35	Vitamin D deficiency: concern for rheumatoid arthritis and COVID-19?. Molecular and Cellular Biochemistry, 2021, 476, 4351-4362.	3.1	4
36	Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020. Chronic Diseases and Translational Medicine, 2021, 7, 220-226.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 169-180.	1.2	7
38	Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 26-35.	1.2	1
39	Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. <i>Antiviral Research</i> , 2021, 192, 105115.	4.1	34
40	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
41	Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. <i>Pharmacoeconomics</i> , 2021, 39, 1309-1325.	3.3	6
42	Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. <i>Cancers</i> , 2021, 13, 4320.	3.7	11
43	Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021, 2, 423-433.	5.0	43
44	Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 26-35.	1.2	1
45	Treatment of double-refractory multiple myeloma. <i>Oncogematologiya</i> , 2021, 16, 58-73.	0.3	4
46	New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021, 154, 1-3.	2.8	1
47	Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials. <i>European Journal of Cancer</i> , 2021, 154, 7-10.	2.8	5
48	Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors. <i>Pharmaceutics</i> , 2021, 13, 1522.	4.5	6
49	Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. <i>Frontiers in Oncology</i> , 2021, 11, 716751.	2.8	2
50	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	2.2	8
51	The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 2040620721110196.	2.5	8
52	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. <i>Cancers</i> , 2021, 13, 5154.	3.7	30
53	Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article. <i>Cancers</i> , 2021, 13, 5210.	3.7	6
54	Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. <i>Cancers</i> , 2021, 13, 5886.	3.7	4

#	ARTICLE	IF	CITATIONS
55	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CART cell therapy for multiple myeloma patients. Hematology, Transfusion and Cell Therapy, 2021, 43, S30-S34.	0.2	1
57	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. British Journal of Cancer, 2022, 126, 718-725.	6.4	21
58	Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials. Frontiers in Pharmacology, 2021, 12, 758992.	3.5	5
59	Updates in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 648-651.	4.9	1
60	Multiples Myelom: Immer mehr Optionen. , 0, , .		0
61	Targeting XPO1-Dependent Nuclear Export in Cancer. Biochemistry (Moscow), 2022, 87, S178-S191.	1.5	2
62	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomarker Research, 2022, 10, 1.	6.8	22
63	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	1.4	16
65	Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia, 2022, 36, 601-612.	7.2	11
66	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 442-459.	0.4	7
67	Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. BioDrugs, 2022, 36, 13-25.	4.6	5
68	Diagnosis and Management of Multiple Myeloma. JAMA - Journal of the American Medical Association, 2022, 327, 464.	7.4	308
69	Role of CBL Mutations in Cancer and Non-Malignant Phenotype. Cancers, 2022, 14, 839.	3.7	11
70	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e526-e531.	0.4	10
71	<i>Ex vivo</i> drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Molecular Oncology, 2022, 16, 1241-1258.	4.6	7
72	The serendipitous integration of small boron-embedded molecules into medicinal chemistry. , 2022, , 321-410.		0
73	Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210810.	3.2	7
74	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	2.5	2

#	ARTICLE	IF	CITATIONS
75	Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis". <i>Annals of Hematology</i> , 2022, , 1.	1.8	0
77	Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. <i>Molecules</i> , 2022, 27, 2201.	3.8	11
78	New and emerging pharmacotherapies for management of multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	1.0	1
79	A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation. <i>American Journal of Case Reports</i> , 2022, 23, e935353.	0.8	2
80	Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 243-250.	2.0	4
81	How I treat <sc>triple</sc> refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	2.5	9
82	Patients with multiple myeloma or monoclonal gammopathy of undetermined significance" diagnosis, treatment, and follow-up. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2022, , .	0.9	2
83	Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. <i>Blood Cancer Journal</i> , 2022, 12, 52.	6.2	8
84	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
85	Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. <i>BMC Medicine</i> , 2022, 20, 108.	5.5	7
86	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
87	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma" the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.	6.2	28
88	Efficacy and tolerability of <sc>once</sc> weekly selinexor, bortezomib, and dexamethasone in comparison with standard <sc>twice</sc> weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <sc>BOSTON</sc> study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
89	A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210875.	3.2	4
90	Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. <i>Blood Cancer Journal</i> , 2022, 12, 46.	6.2	13
91	Selinexor and COVID-19: The Neglected Warden. <i>Frontiers in Pharmacology</i> , 2022, 13, 884228.	3.5	20
92	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C" Mutant Cancers. <i>Cancer Research Communications</i> , 2022, 2, 342-352.	1.7	12
93	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	4.1	208

#	ARTICLE	IF	CITATIONS
94	Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 144-150.	0.3	2
96	An update on novel multiple myeloma targets. Expert Review of Hematology, 2022, 15, 519-537.	2.2	1
97	Updates in the Treatment of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 584-588.	4.9	0
98	Pathogenesis and treatment of multiple myeloma. MedComm, 2022, 3, .	7.2	8
99	The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. Translational Oncology, 2022, 22, 101448.	3.7	5
100	Therapeutics to harness the immune microenvironment in multiple myeloma. Cancer Drug Resistance (Alhambra, Calif ), 2022, 5, 647-61.	2.1	6
101	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology, 2022, , .	3.0	7
102	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	3.1	3
103	Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series. American Journal of Case Reports, 0, 23, .	0.8	2
104	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. Archives of Virology, 0, , .	2.1	1
105	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072211006.	2.5	4
106	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	6.2	16
107	Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 2022, 36, 2189-2195.	7.2	6
108	Treatment horizon in multiple myeloma. European Journal of Haematology, 2022, 109, 425-440.	2.2	6
109	No needles needed: All-oral therapy options for relapsed & refractory multiple myeloma. Blood Reviews, 2022, , 100993.	5.7	0
110	Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. Current Opinion in Oncology, 2022, 34, 524-530.	2.4	2
112	The NF-ÎB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines, 2022, 10, 2233.	3.2	7
113	Selinexorâ€¢based regimens in patients with multiple myeloma after prior antiâ€¢Bâ€¢cell maturation antigen treatment. EJHaem, 2022, 3, 1270-1276.	1.0	7



#	ARTICLE	IF	CITATIONS
114	Recent advances in the treatment of multiple myeloma: a brief review. Faculty Reviews, 0, 11, .	3.9	3
115	Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematology, 2022, 9, e634-e636.	4.6	3
116	Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14). Npj Precision Oncology, 2022, 6, .	5.4	9
118	New drug: Selinexor for multiple myeloma. Australian Prescriber, 0, , .	1.0	0
119	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	7.2	25
120	Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature. Annals of Hematology, 2022, 101, 2601-2610.	1.8	1
121	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in Oncology, 0, 12, .	2.8	3
123	Novel and Experimental Clone-Directed Therapies. , 2022, , 355-376.		0
124	The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Review of Proteomics, 2022, 19, 235-246.	3.0	3
125	The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma. Current Hematologic Malignancy Reports, 2022, 17, 306-318.	2.3	3
126	Management of Relapsed and Refractory Multiple Myeloma: Recent advances. Indian Journal of Medical and Paediatric Oncology, 2022, 43, 458-472.	0.2	0
127	Fitness and frailty in myeloma. Hematology American Society of Hematology Education Program, 2022, 2022, 337-348.	2.5	4
128	The first relapse in multiple myeloma: how to pick the next best thing. Hematology American Society of Hematology Education Program, 2022, 2022, 560-568.	2.5	0
129	HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLoS ONE, 2022, 17, e0274704.	2.5	2
130	The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Annals of Hematology, 2023, 102, 1-11.	1.8	12
131	Inhibition of proteasome, but not lysosome, upregulates organic anion transporter 3 in vitro and in vivo. Biochemical Pharmacology, 2023, 208, 115387.	4.4	3
132	Selinexorâ€™Bortezomibâ€™Dexamethasone: A Review in Previously Treated Multiple Myeloma. Targeted Oncology, 2023, 18, 303-310.	3.6	1
133	The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies. Journal of Cancer Survivorship, 0, , .	2.9	1



#	ARTICLE	IF	CITATIONS
134	Real-world assessment of treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma in an Italian haematological tertiary care centre. <i>British Journal of Haematology</i> , 2023, 201, 432-442.	2.5	4
135	How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> , 2023, 15, 155.	3.7	3
136	Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2645.	4.1	4
137	Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. , 0, , .		0
138	Subgroups and precision in myeloma. <i>Journal of Cancer Policy</i> , 2023, 35, 100407.	1.4	0
139	E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114305.	5.6	3
140	A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. <i>European Journal of Haematology</i> , 2023, 110, 564-570.	2.2	4
141	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
142	Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. <i>Current Oncology</i> , 2023, 30, 2322-2347.	2.2	10
143	Accuracy of a time-of-flight (ToF) imaging system for monitoring deep-inspiration breath-hold radiotherapy (DIBH-RT) for left breast cancer patients. <i>Physical and Engineering Sciences in Medicine</i> , 2023, 46, 339-352.	2.4	0
144	Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis. <i>Hematology</i> , 2023, 28, .	1.5	0
145	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	5
146	Management of Relapsed/Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. <i>Cancers</i> , 2023, 15, 2160.	3.7	3
147	Current Main Topics in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 2203.	3.7	1
148	Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. <i>Haematologica</i> , 0, , .	3.5	0
149	Targeted therapy. , 2023, , 205-411.		0
152	APEX3 â€“ An Optimized Tool for Rapid and Unbiased Proximity Labeling. <i>Journal of Molecular Biology</i> , 2023, 435, 168145.	4.2	1
153	Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. <i>Cancers</i> , 2023, 15, 2948.	3.7	1

#	ARTICLE	IF	CITATIONS
154	Selinexor in patients with advanced and recurrent endometrial cancer. <i>Current Problems in Cancer</i> , 2023, 47, 100963.	2.0	4
155	Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e286-e296.e4.	0.4	2
156	Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis. <i>Hematology</i> , 2023, 28, .	1.5	0
157	Selinexor and Other Selective Inhibitors of Nuclear Export (SINEs)â€”A Novel Approach to Target Hematologic Malignancies and Solid Tumors. , 2023, 2, 459-476.		0
158	A review of the mechanism of action, safety, and efficacy of selinexor in multiple myeloma. , 0, , .		0
159	Difficultâ€”toâ€”treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. <i>EJHaem</i> , 0, , .	1.0	0
160	Impact of treatment effect on MRD and PFS: an aggregate analysis from randomized clinical trials in multiple myeloma. <i>Blood Advances</i> , 0, , .	5.2	0
161	Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis. <i>BMJ Open</i> , 2023, 13, e067966.	1.9	0
162	Association of selinexor dose reductions with clinical outcomes in the BOSTON study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.4	1
163	ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. <i>Haematologica</i> , 2024, 109, 867-876.	3.5	0
164	Multiple Myeloma: Current Clinical Landscape and Compounding Costs. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 201-215.	2.3	0
165	Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy. <i>IUBMB Life</i> , 2024, 76, 4-25.	3.4	1
166	Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
167	Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 844-849.	0.4	1
168	Nuclear Transport Inhibitors. , 2023, , 111-120.		3
169	Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase). <i>Expert Opinion on Drug Safety</i> , 2024, 23, 247-255.	2.4	0
170	Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 5400-5410.	1.6	6
171	New Biological Therapies for Multiple Myeloma. <i>Annual Review of Medicine</i> , 2024, 75, .	12.2	0

#	ARTICLE	IF	CITATIONS
172	The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
173	Nuclear transport proteins: structure, function, and disease relevance. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	2
174	A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 1049-1071.	2.4	0
175	Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line. <i>Hematology American Society of Hematology Education Program</i> , 2023, 2023, 443-449.	2.5	0
176	Multiple Myeloma in 2023 Ways: From Trials to Real Life. <i>Current Oncology</i> , 2023, 30, 9710-9733.	2.2	1
177	Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. <i>Blood Cancer Journal</i> , 2023, 13, .	6.2	2
178	NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment. <i>Cells</i> , 2023, 12, 2748.	4.1	0
179	Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action. <i>Cancers</i> , 2024, 16, 84.	3.7	0
180	Treatment of multiple myeloma with selinexor: a review. <i>Therapeutic Advances in Hematology</i> , 2024, 15, .	2.5	0
181	Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0
182	Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study <scp>DARIA</scp>. <i>American Journal of Hematology</i> , 2024, 99, 396-407.	4.1	0
183	Co-expression analysis of transcriptomic data from cancer and healthy specimens reveals rewiring of proteasome genes and an interaction with the XPO1 gene across several tumour types. <i>Translational Medicine Communications</i> , 2024, 9, .	1.4	0
184	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
185	Selinexor for the treatment of patients with relapsed or refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2024, 30, 535-546.	0.9	0
186	Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). <i>Life</i> , 2024, 14, 384.	2.4	0
187	Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. <i>Blood Cancer Journal</i> , 2024, 14, .	6.2	0
188	Selinexor in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2024, 25, 421-434.	1.8	0